![Will Dusk (ASX: DSK) Rise From The Shadows?](https://f9s5e5c4.delivery.rocketcdn.me/app/uploads/2023/12/dusk-min-300x133.jpeg)
Will Dusk (ASX: DSK) Rise From The Shadows?
The Dusk (ASX: DSK) share price is now much lower than it first listed in late 2020. Is it a sound investment opportunity?
The Dusk (ASX: DSK) share price is now much lower than it first listed in late 2020. Is it a sound investment opportunity?
Acusensus (ASX: ACE) uses advanced technology to surveil and photograph drivers while they breaching road rules.
RAS Technology Holdings is showing stellar revenue growth; but what are the risks
Raymond Jang brings you his in-person impressions from attending the 2023 Supply Network AGM.
The share price of Xero (ASX: XRO) fell sharply after the H1 FY 2024 results; but does that make it cheap?
As former shareholders of Ensurance (ASX: ENA) we now own PSC Insurance (ASX: PSI) shares accumulated at a discount to current prices.
Vysarn’s AGM update gives us insight into to why the share price has risen, and where the company is headed.
At the FY 2023 Annual General Meeting, Altium (ASX: ALU) highlighted its focus on penetrating the enterprise market.
The FY 2023 Pro Medicus (ASX: PME) AGM further demonstrated the high quality of the business and the good nature of the leadership group.
The AGM was a good opportunity to catch up with company leadership and other shareholders.
Maxiparts (ASX: MXI) is on another acquisition hunt, vacuuming two businesses. One seems to be a great business but is it a sound investment?
Chrysos Corporation (ASX: C79) is emerging as a fast growing disruptor in a growing industry. Here’s why its watchlist worthy.
Hitech Group Australia (ASX: HIT) has achieved epic earnings growth over the past few years; and pays a decent dividend yield to boot.
3 ASX stocks are in the running to win the Australian Exporter of the Year for 2023. Are these ASX stocks on the cusp of greatness or major disappointment?
Here are some of the small-cap Annual General Meetings coming up this month.
The Nanosonics (ASX: NAN) AGM reveals challenging conditions for the hospital industry but management is buoyed by CORIS progress.
Alcidion (ASX: ALC) is raising capital due delays in NHS procurement.
The Mader (ASX: MAD) update for Q1 FY2024 showed strong momentum however at current share price levels, is it a sound investment?
The Adore Beauty (ASX: ABY) trading update for Q1 FY2024 shows promise but is it capable of becoming more than a mediocre business in the long run?
DUG Technology (ASX: DUG) posted strong results in Q1 FY2024, but is this down to the business or external factors?